We used the previously validated high-definition single cell assay (HDSCA) workflow to investigate the clinical significance of CTCs in ERBB2 mutant, non-amplified BC patients starting neratinib and fulvestrant combination therapy. The gene discussed is ERBB2; the disease is breast cancer.